Table 2 Baseline characteristics of patients
Characteristics | Treatment success | Treatment failure | p-value | Characteristics | Treatment success | Treatment failure | p-value |
|---|---|---|---|---|---|---|---|
(n = 12) | (n = 14) | (n = 12) | (n = 14) | ||||
Age (year) | EBRT field, n (%) | 0.46 | |||||
Median (range) | 61 (47–89) | 49 (33–72) | 0.03 | Whole pelvis | 11 (92) | 14 (100) | |
ECOG Performance Status, n (%) | 0.78 | Small pelvis | 1 (8) | 0 (0) | |||
0 | 10 (83) | 12 (86) | Chemotherapy, n (%) | 0.58 | |||
1 | 1 (8) | 2 (14) | 0 mg/m2 | 2 (17) | 1 (7) | ||
2 | 1 (8) | 0 (0) | ≥ 100 mg/m2 | 10 (83) | 13 (93) | ||
Histology, n (%) | 1.00 | EBRT dose, n (%) | 0.20 | ||||
Squamous cell carcinoma | 12 (100) | 13 (93) | 1.8 Gy × 28 fr | 10 (83) | 14 (100) | ||
Adenocarcinoma | 0 (0) | 1 (7) | 1.6 Gy × 31 fr | 1 (8) | 0 (0) | ||
Stage (FIGO 2009), n (%) | 0.51 | 2.0 Gy × 15 fr | 1 (8) | 0 (0) | |||
I | 1 (8) | 3 (21) | HDR-ICBT dose at Point A, n (%) | 0.59 | |||
II | 6 (50) | 9 (64) | 5 Gy × 2 fr | 1 (8) | 0 (0) | ||
III | 3 (25) | 1 (7) | 5 Gy × 4 fr | 0 (0) | 1 (7) | ||
IV | 2 (17) | 1 (7) | 5 Gy × 5 fr | 3 (25) | 3 (21) | ||
Tumor diameter, n (%) | 1.00 | 5 Gy × 6 fr | 8 (67) | 6 (43) | |||
< 4 cm | 2 (17) | 2 (14) | 5 Gy × 7 fr | 0 (0) | 2 (14) | ||
≥ 4 cm | 10 (83) | 12 (86) | 5 Gy × 8 fr | 0 (0) | 1 (7) | ||
Lymph node metastasis, n (%) | 0.23 | 5 Gy × 5 fr. + 6 Gy × 1 fr | 0 (0) | 1 (7) | |||
Negative | 7 (58) | 4 (29) | Treatment effect, n (%) | 0.02 | |||
Positive | 5 (42) | 10 (71) | CR | 12 (100) | 8 (57) | ||
Distant metastasis, n (%) | 0.58 | PR | 0 (0) | 6 (43) | |||
Negative | 10 (83) | 13 (93) | SD | 0 (0) | 0 (0) | ||
Positive | 2 (17) | 1 (7) | PD | 0 (0) | 0 (0) | ||